Aprepitant and Tecentriq drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Aprepitant (aprepitant) and Tecentriq (atezolizumab). Common drug interactions include electrolyte imbalance among females and oedema peripheral among males.

The phase IV clinical study analyzes what interactions people have when they take Aprepitant and Tecentriq. It is created by eHealthMe based on reports of 45 people who take the same drugs from the FDA, and is updated regularly.

What is Aprepitant?

Aprepitant has active ingredients of aprepitant. eHealthMe is studying from 6,992 Aprepitant users. Check the latest studies of Aprepitant.

What is Tecentriq?

Tecentriq has active ingredients of atezolizumab. eHealthMe is studying from 12,796 Tecentriq users. Check the latest studies of Tecentriq.

On Jul, 13, 2026

45 people who take Aprepitant and Tecentriq together, and have interactions are studied.

Aprepitant and Tecentriq drug interactions.

What are the common drug interactions of Aprepitant and Tecentriq, by gender? *:

female:

Electrolyte imbalance
Hypoaesthesia (reduced sense of touch or sensation)
Neuropathy peripheral (surface nerve damage)
Pain
Aortic arteriosclerosis (hardening of the aortic arteries)
Atrioventricular block complete (heart block complete)
Blood creatine phosphokinase increased
Blood pressure increased
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Hepatic enzyme increased

male:

Oedema peripheral (superficial swelling)
Subileus
Lower gastrointestinal haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding)
Malaise (a feeling of general discomfort or uneasiness)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
Skin neoplasm bleeding (bleeding skin tumour)
Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
White blood cell count decreased
Disease progression

What are the common drug interactions of Aprepitant and Tecentriq, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Pyrexia (fever)
Dysphonia (speech disorder attributable to a disorder of phonation)
Erythema multiforme (a type of hypersensitivity reaction)
Guillain-barre syndrome (the body's immune system attacks its peripheral nervous system)
Hepatocellular injury (liver injury)
Neutropenia (an abnormally low number of neutrophils)
Rash
Skin disorder (skin disease)

50-59:

Oedema peripheral (superficial swelling)
Subileus
Electrolyte imbalance
Hypoaesthesia (reduced sense of touch or sensation)
Neuropathy peripheral (surface nerve damage)
Pain
Anaemia (lack of blood)
Asthenia (weakness)
Cerebral disorder (brain disease)
Dizziness

60+:

Neutropenia (an abnormally low number of neutrophils)
Anaemia (lack of blood)
Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
Skin neoplasm bleeding (bleeding skin tumour)
Upper gastrointestinal haemorrhage (upper gastrointestinal bleeding)
White blood cell count decreased
Aortic arteriosclerosis (hardening of the aortic arteries)
Atrioventricular block complete (heart block complete)
Blood creatine phosphokinase increased
Blood pressure increased

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 14 people, 31.11%
Lung Cancer - Small Cell (lung cancer): 12 people, 26.67%
High Blood Pressure: 12 people, 26.67%
Insomnia (sleeplessness): 11 people, 24.44%
Diabetes: 11 people, 24.44%
Bronchial Carcinoma (lung cancer): 10 people, 22.22%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 7 people, 15.56%
Constipation: 4 people, 8.89%
Pain: 3 people, 6.67%
Fever: 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Aprepitant and Tecentriq?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously